Intraluminal brachytherapy using 125I seed strand combined with PTBD and Hepatic arterial infusion chemotherapy for unresectable Bismuth-Corlette III and IV stage hilar cholangiocarcinoma
Brachytherapy · 2025
DOI: 10.1016/j.brachy.2024.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2025. Verfasst von Zi-Han Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China; Shanghai Institute of Medical Imaging, Shangha…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Iodine Radioisotopes, Brachytherapy, Klatskin Tumor. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: To evaluate the safety and efficacy of 125I seed strand combined with percutaneous transhepatic biliary drainage (PTBD) and hepatic arterial infusion chemotherapy (HAIC) for unresectable Bismuth-Corlette III and IV stage hilar cholangiocarcinoma (HCCA). METHODS: From January 2018 to December 2021, a total of 128 Bismuth-Corlette III and IV stage HCCA patients with obstructive jaundice were included in this single-center retrospective study. Forty-eight patients underwent 125I seed strand combined with PTBD and HAIC (group A). The mean intended dose (r = 10 mm; z = 0; 240 days) in group A was 63.8 ± 0.6 Gy. Eighty cases underwent PTBD plus HAIC (group B). Median overall survival (OS) and median bile duct patency time (BDPT) were compared between the two groups. RESULTS: In the propensity-score matched (PSM) cohort, the median OS and median BDPT were significantly longer in group A than in group B (44 PSM pairs; OS, 13.6 ± 0.4 vs. 8.7 ± 1.4 months, p < 0.001; BDPT, 12.1 ± 0.5 vs. 6.4 ± 0.7 months, p < 0.001). Multivariate analysis revealed that the treatment regimen was an independent prognostic factor of OS. There were no serious complications related to 125I seed strand implantation. CONCLUSIONS: 125I seed strand combined with PTBD and HAIC for unresectable Bismuth-Corlette III and IV stage HCCA is safe and effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China; Shanghai Institute of Medical Imaging, Shanghai, 200032, China; National Clinical Research Center for Interventional…
- Institue of Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address: lifuyou@sjtu.edu.cn.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhang, Z. H., Li, M., Sun, H. Y., Wang, F. H., Yang, M. J., Yan, Z. P., Li, F. Y., & Liu, L. X. (2025). Intraluminal brachytherapy using 125I seed strand combined with PTBD and Hepatic arterial infusion chemotherapy for unresectable Bismuth-Corlette III and IV stage hilar cholangiocarcinoma. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.12.004
Vancouver
Zhang ZH, Li M, Sun HY, Wang FH, Yang MJ, Yan ZP, et al. Intraluminal brachytherapy using 125I seed strand combined with PTBD and Hepatic arterial infusion chemotherapy for unresectable Bismuth-Corlette III and IV stage hilar cholangiocarcinoma. Brachytherapy. 2025. doi:10.1016/j.brachy.2024.12.004
BibTeX
@article{Zhang2025,
author = {Zhang, Zi-Han and Li, Min and Sun, Hui-Yi and Wang, Fei-Hang and Yang, Min-Jie and Yan, Zhi-Ping and Li, Fu-You and Liu, Ling-Xiao},
title = {Intraluminal brachytherapy using 125I seed strand combined with PTBD and Hepatic arterial infusion chemotherapy for unresectable Bismuth-Corlette III and IV stage hilar cholangiocarcinoma},
journal = {Brachytherapy},
year = {2025},
doi = {10.1016/j.brachy.2024.12.004}
}
EUVIMED